Actinium Pharmaceuticals Inc (ATNM)

[blukky]

NEWS - Actinium Pharmaceuticals announces treatment of first patient in novel combination trial of actimab-A plus CLAG-M.


Fri Sep 21 01:11:16 2018 EDT
On 13 Jun 2018 , Actinium Pharmaceuticals Inc announced that the Medical College of Wisconsin has treated its first patient in a Phase 1 trial studying Actinium's Actimab-A in combination with CLAG-M for patients with relapsed or refractory (r/r) acute myeloid leukaemia (AML). This Phase 1 dose-escalation trial will study a single administration of Actimab-A following treatment of CLAG-M and will evaluate safety and tolerability, response rates, rates of bone marrow transplant (BMT), progression-free survival (PFS), and overall survival (OS). Actimab-A is an ARC or Antibody Radio-Conjugate comprised of the anti-CD33 monoclonal antibody lintuzumab labelled with the radioisotope actinium-225. CD33 is a marker expressed on AML cells of virtually all AML patients. Actinium's CD33 ARC has been studied in over 100 patients to date and is the only CD33 targeting agent being studied in a broad range of diseases in which the CD33 antigen is expressed including AML, myelodysplastic syndrome (MDS) and multiple myeloma. CLAG-M is a salvage chemotherapy regimen commonly used to treat patients with AML that consists of cladribine, cytarabine, filgrastim, and mitoxantrone. Original Source: Actinium Pharmaceuticals , 2018. Found on website: http://www.globenewswire.com.
SID(ELSEVIERdcc963b2901b9ae)


ATNM
CT/ebf CT/ebf.bus CT/ebf.bus.new CT/ebf.bus.new.pdt IC/hlth IC/hlth.phrm IC/svcs IC/svcs.educ II/biotech.immunoth II/hcare.biopharm II/hcare.biotech II/hcare.pharma IS/haw IS/haw.approval IS/haw.cancer IS/haw.disease IS/haw.drugapp IS/haw.drugs IS/haw.healthsc IS/haw.pharmdev IS/haw.reg IS/haw.treat

**CS-B-10